<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7351767</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">32651411</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">7351767</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">68266</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1038/s41598-020-68266-x</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Patient characteristics.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Patient characteristics.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">PD-HI N = 20</th><th align="left">PD-LI N = 25</th><th align="left">Control N = 21</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Gender, F/M</td><td align="left">12/8</td><td align="left">15/10</td><td align="left">8/13</td><td align="left">0.27<sup>a</sup></td></tr><tr><td align="left">Age, years</td><td align="left">63.9 ± 10.2</td><td align="left">65.8 ± 8.5</td><td align="left">64.3 ± 10.3</td><td align="left">0.78<sup>b</sup></td></tr><tr><td align="left">Education, years</td><td align="left">12 (12–15.5)</td><td align="left">12 (12–14)</td><td align="left">12 (12–15)</td><td align="left">0.88<sup>c</sup></td></tr><tr><td align="left">BIS-11 score</td><td align="left"><p>66.0 ± 4.3</p><p>65 (62.3–69)</p></td><td align="left"><p>54.4 ± 5.1</p><p>56 (50–58.5)</p></td><td align="left"><p>56.6 ± 10.6</p><p>57 (47–67)</p></td><td align="left">&lt; 0.0001<sup>c</sup></td></tr><tr><td align="left">Iat</td><td align="left">17.1 ± 2.4</td><td align="left">13.8 ± 1.8</td><td align="left">14.0 ± 4.0</td><td align="left">0.0001<sup>b</sup></td></tr><tr><td align="left">Im</td><td align="left">22.2 ± 2.7</td><td align="left">18.6 ± 3.0</td><td align="left">19.8 ± 4.2</td><td align="left">0.0031<sup>b</sup></td></tr><tr><td align="left">Inp</td><td align="left">26.8 ± 3.1</td><td align="left">22.0 ± 3.2</td><td align="left">22.8 ± 5.4</td><td align="left">0.0005<sup>b</sup></td></tr><tr><td align="left">Age at onset, years</td><td align="left">56.8 ± 8.6</td><td align="left">58.8 ± 2.1</td><td align="left">–</td><td align="left">0.47<sup>d</sup></td></tr><tr><td align="left">Duration, years</td><td align="left">6.3 (2.8 − 10.3)</td><td align="left">6.3 (2.4–9.0)</td><td align="left">–</td><td align="left">0.89<sup>e</sup></td></tr><tr><td align="left">LEDD, mg</td><td align="left">463 (356–623)</td><td align="left">475 (319–663)</td><td align="left">–</td><td align="left">0.97<sup>e</sup></td></tr><tr><td align="left">Levodopa, mg</td><td align="left">300 (38–438)</td><td align="left">300 (300–350)</td><td align="left">–</td><td align="left">0.85<sup>e</sup></td></tr><tr><td align="left">Dopamine agonist, mg/LEDD</td><td align="left">150 (0–285)</td><td align="left">150 (19–233)</td><td align="left">–</td><td align="left">0.73<sup>e</sup></td></tr><tr><td align="left">MMSE score</td><td align="left">29.5 (28.25–30)</td><td align="left">30 (29–30)</td><td align="left">NA</td><td align="left">0.38<sup>e</sup></td></tr><tr><td align="left">FAB score</td><td align="left">15.5 (13–17)</td><td align="left">16 (14–17)</td><td align="left">NA</td><td align="left">0.52<sup>e</sup></td></tr><tr><td align="left">Stroop</td><td align="left">8 (4.5–13.8)</td><td align="left">10 (5.5–16.5)</td><td align="left">NA</td><td align="left">0.37<sup>c</sup></td></tr><tr><td align="left">MDS-UPDRS score</td><td align="left">47.6 ± 15.2</td><td align="left">43.6 ± 25.7</td><td align="left">NA</td><td align="left">0.55<sup>d</sup></td></tr><tr><td align="left">Part 1</td><td align="left">10 (6.25–13)</td><td align="left">7 (5.5–9.5)</td><td align="left">NA</td><td align="left">0.047<sup>e</sup></td></tr><tr><td align="left">Part 2</td><td align="left">12.5 (9.3–16.8)</td><td align="left">9 (4–12.5)</td><td align="left">NA</td><td align="left">0.044<sup>e</sup></td></tr><tr><td align="left">Part 3</td><td align="left">22.2 ± 7.7</td><td align="left">23.8 ± 15.9</td><td align="left">0</td><td align="left">0.69<sup>d</sup></td></tr><tr><td align="left">Part 4</td><td align="left">0 (0–2.75)</td><td align="left">1 (0–5)</td><td align="left">NA</td><td align="left">0.17<sup>e</sup></td></tr></tbody></table><table-wrap-foot><p>Continuous variables are presented as means ± standard deviation and/or medians (interquartile range), depending on data distribution.</p><p><italic>BIS-11</italic> Barratt impulsiveness scale 11th version, <italic>LEDD</italic> levodopa-equivalent daily dose, <italic>MMSE</italic> mini-mental state examination, <italic>FAB</italic> frontal assessment battery, <italic>MDS-UPDRS</italic> movement disorder society-sponsored unified Parkinson’s disease-rating scale, <italic>NA</italic> not available.</p><p><sup>a</sup>Fisher’s exact test.</p><p><sup>b</sup>One-way analysis of variance.</p><p><sup>c</sup>Kruskal–Wallis test.</p><p><sup>d</sup><italic>t</italic>-test between PD-HI and PD-LI.</p><p><sup>e</sup>Wilcoxon rank-sum test between PD-HI and PD-LI.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Patient characteristics.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">PD-HI N = 20</th><th align="left">PD-LI N = 25</th><th align="left">Control N = 21</th><th align="left">P value</th></tr></thead><tbody><tr><td align="left">Gender, F/M</td><td align="left">12/8</td><td align="left">15/10</td><td align="left">8/13</td><td align="left">0.27a</td></tr><tr><td align="left">Age, years</td><td align="left">63.9 ± 10.2</td><td align="left">65.8 ± 8.5</td><td align="left">64.3 ± 10.3</td><td align="left">0.78b</td></tr><tr><td align="left">Education, years</td><td align="left">12 (12–15.5)</td><td align="left">12 (12–14)</td><td align="left">12 (12–15)</td><td align="left">0.88c</td></tr><tr><td align="left">BIS-11 score</td><td align="left">66.0 ± 4.365 (62.3–69)</td><td align="left">54.4 ± 5.156 (50–58.5)</td><td align="left">56.6 ± 10.657 (47–67)</td><td align="left">&lt; 0.0001c</td></tr><tr><td align="left">Iat</td><td align="left">17.1 ± 2.4</td><td align="left">13.8 ± 1.8</td><td align="left">14.0 ± 4.0</td><td align="left">0.0001b</td></tr><tr><td align="left">Im</td><td align="left">22.2 ± 2.7</td><td align="left">18.6 ± 3.0</td><td align="left">19.8 ± 4.2</td><td align="left">0.0031b</td></tr><tr><td align="left">Inp</td><td align="left">26.8 ± 3.1</td><td align="left">22.0 ± 3.2</td><td align="left">22.8 ± 5.4</td><td align="left">0.0005b</td></tr><tr><td align="left">Age at onset, years</td><td align="left">56.8 ± 8.6</td><td align="left">58.8 ± 2.1</td><td align="left">–</td><td align="left">0.47d</td></tr><tr><td align="left">Duration, years</td><td align="left">6.3 (2.8 − 10.3)</td><td align="left">6.3 (2.4–9.0)</td><td align="left">–</td><td align="left">0.89e</td></tr><tr><td align="left">LEDD, mg</td><td align="left">463 (356–623)</td><td align="left">475 (319–663)</td><td align="left">–</td><td align="left">0.97e</td></tr><tr><td align="left">Levodopa, mg</td><td align="left">300 (38–438)</td><td align="left">300 (300–350)</td><td align="left">–</td><td align="left">0.85e</td></tr><tr><td align="left">Dopamine agonist, mg/LEDD</td><td align="left">150 (0–285)</td><td align="left">150 (19–233)</td><td align="left">–</td><td align="left">0.73e</td></tr><tr><td align="left">MMSE score</td><td align="left">29.5 (28.25–30)</td><td align="left">30 (29–30)</td><td align="left">NA</td><td align="left">0.38e</td></tr><tr><td align="left">FAB score</td><td align="left">15.5 (13–17)</td><td align="left">16 (14–17)</td><td align="left">NA</td><td align="left">0.52e</td></tr><tr><td align="left">Stroop</td><td align="left">8 (4.5–13.8)</td><td align="left">10 (5.5–16.5)</td><td align="left">NA</td><td align="left">0.37c</td></tr><tr><td align="left">MDS-UPDRS score</td><td align="left">47.6 ± 15.2</td><td align="left">43.6 ± 25.7</td><td align="left">NA</td><td align="left">0.55d</td></tr><tr><td align="left">Part 1</td><td align="left">10 (6.25–13)</td><td align="left">7 (5.5–9.5)</td><td align="left">NA</td><td align="left">0.047e</td></tr><tr><td align="left">Part 2</td><td align="left">12.5 (9.3–16.8)</td><td align="left">9 (4–12.5)</td><td align="left">NA</td><td align="left">0.044e</td></tr><tr><td align="left">Part 3</td><td align="left">22.2 ± 7.7</td><td align="left">23.8 ± 15.9</td><td align="left">0</td><td align="left">0.69d</td></tr><tr><td align="left">Part 4</td><td align="left">0 (0–2.75)</td><td align="left">1 (0–5)</td><td align="left">NA</td><td align="left">0.17e</td></tr></tbody></table></div>Continuous variables are presented as means ± standard deviation and/or medians (interquartile range), depending on data distribution.BIS-11 Barratt impulsiveness scale 11th version, LEDD levodopa-equivalent daily dose, MMSE mini-mental state examination, FAB frontal assessment battery, MDS-UPDRS movement disorder society-sponsored unified Parkinson’s disease-rating scale, NA not available.aFisher’s exact test.bOne-way analysis of variance.cKruskal–Wallis test.dt-test between PD-HI and PD-LI.eWilcoxon rank-sum test between PD-HI and PD-LI.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Functional connectivity between nucleus accumbens and other regions.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p>Functional connectivity between nucleus accumbens and other regions.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">PD-HI</th><th align="left">PD-LI</th><th align="left">Control</th><th align="left"><italic>p</italic></th></tr></thead><tbody><tr><td align="left" colspan="5"><bold>R Accumbens</bold></td></tr><tr><td align="left">ACC</td><td char="." align="char">0.081 ± 0.133</td><td char="." align="char">0.056 ± 0.102</td><td char="." align="char">0.063 ± 0.118</td><td char="." align="char">0.77</td></tr><tr><td align="left">R Putamen</td><td char="." align="char">0.094 ± 0.118</td><td char="." align="char">0.065 ± 0.117</td><td char="." align="char">0.096 ± 0.108</td><td char="." align="char">0.59</td></tr><tr><td align="left">R Amygdala</td><td char="." align="char">0.061 ± 0.130</td><td char="." align="char"> − 0.010 ± 0.112</td><td char="." align="char">0.034 ± 0.098</td><td char="." align="char">0.12</td></tr><tr><td align="left" colspan="5"><bold>L Accumbens</bold></td></tr><tr><td align="left">ACC</td><td char="." align="char">0.157 ± 0.150</td><td char="." align="char">0.104 ± 0.090</td><td char="." align="char">0.123 ± 0.099</td><td char="." align="char">0.31</td></tr><tr><td align="left">L Putamen</td><td char="." align="char">0.131 ± 0.088</td><td char="." align="char">0.109 ± 0.107</td><td char="." align="char">0.132 ± 0.121</td><td char="." align="char">0.70</td></tr><tr><td align="left">L Amygdala</td><td char="." align="char">0.085 ± 0.102</td><td char="." align="char">0.060 ± 0.115</td><td char="." align="char">0.036 ± 0.109</td><td char="." align="char">0.36</td></tr></tbody></table><table-wrap-foot><p>Continuous variables are presented as means ± standard deviation. Comparisons among the three groups were determined by analysis of variance.</p><p><italic>R</italic> right, <italic>L</italic> left, <italic>ACC</italic> anterior cingulate cortex.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Functional connectivity between nucleus accumbens and other regions.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">PD-HI</th><th align="left">PD-LI</th><th align="left">Control</th><th align="left">p</th></tr></thead><tbody><tr><td align="left" colspan="5">R Accumbens</td></tr><tr><td align="left">ACC</td><td char="." align="char">0.081 ± 0.133</td><td char="." align="char">0.056 ± 0.102</td><td char="." align="char">0.063 ± 0.118</td><td char="." align="char">0.77</td></tr><tr><td align="left">R Putamen</td><td char="." align="char">0.094 ± 0.118</td><td char="." align="char">0.065 ± 0.117</td><td char="." align="char">0.096 ± 0.108</td><td char="." align="char">0.59</td></tr><tr><td align="left">R Amygdala</td><td char="." align="char">0.061 ± 0.130</td><td char="." align="char"> − 0.010 ± 0.112</td><td char="." align="char">0.034 ± 0.098</td><td char="." align="char">0.12</td></tr><tr><td align="left" colspan="5">L Accumbens</td></tr><tr><td align="left">ACC</td><td char="." align="char">0.157 ± 0.150</td><td char="." align="char">0.104 ± 0.090</td><td char="." align="char">0.123 ± 0.099</td><td char="." align="char">0.31</td></tr><tr><td align="left">L Putamen</td><td char="." align="char">0.131 ± 0.088</td><td char="." align="char">0.109 ± 0.107</td><td char="." align="char">0.132 ± 0.121</td><td char="." align="char">0.70</td></tr><tr><td align="left">L Amygdala</td><td char="." align="char">0.085 ± 0.102</td><td char="." align="char">0.060 ± 0.115</td><td char="." align="char">0.036 ± 0.109</td><td char="." align="char">0.36</td></tr></tbody></table></div>Continuous variables are presented as means ± standard deviation. Comparisons among the three groups were determined by analysis of variance.R right, L left, ACC anterior cingulate cortex.</transformed-table></extracted-table></extracted-tables-set>